Targovax ASA

Sep 27, 2018

Targovax Announces Interim Results From Phase I Trial of ONCOS-102 in Checkpoint Inhibitor Refractory Melanoma

Sep 27, 2018

Targovax to Host Key Opinion Leader Symposium on Oncolytic Viruses in New York City, 11 October 2018

Sep 12, 2018

Targovax Announces Publication of New Oncolytic Virus Data in the Journal of Medical Virology and Cancer Gene Therapy

Aug 23, 2018

Targovax ASA: Second Quarter and First Half Year 2018 Results

Jul 12, 2018

Targovax and SOTIO Announce First Patient Dosed in Phase I/II Combination Trial of ONCOS-102 With DCVAC

Jun 19, 2018

Targovax Granted EU Patent for Mutant-RAS Neoantigen Platform 2nd Generation Product TG02

Jun 12, 2018

Targovax Hosts Conference Call 12 June 2018

Jun 11, 2018

Targovax Strengthens Focus on ONCOS Oncolytic Virus Development Program

Jun 04, 2018

Targovax to Present at Jefferies 2018 Global Healthcare Conference

May 24, 2018

Targovax Strengthens 2-year Survival Rate in Resected Pancreatic Cancer With TG01